Page 8 - Ben Brahim News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022 myvac TG4001 : expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data BT-001 Invir.IO platform following the partial sale of the stake in Tasly BioPharmaceuticals in 2020 Conference call in English scheduled today at 6:00 p.m. CET Video conference in French on March 10 at 10:00 a.m. CET (details at the end of the release) Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immun...

Provided by Business Wire Mar 1, 2021 6:30 AM UTC Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the first patient in a Phase I...